Place of topical antibacterial therapy for exacerbation of chronic bronchit

Abstract

The questions not only about the optimal choice of antibacterial therapy in case of infection exacerbation of chronic bronchitis (CB), but also about the place of topical antibacterial drugs (TAD) are considered in this article. The aim of the study was to evaluate the clinical efficacy of combined inhalation TAD with mucolytic effect of thiamphenicol glycinate acetylcysteinate in patients with infectious exacerbation of CB. Methods. The study included patients (n = 99) with the CB, observed at the City Consulting and Diagnostic Pulmonology Center (Chelyabinsk). Two groups of patients were formed: 1^st group (n = 44; mean age 46.3 ± 3.5 years) – subjects who received systemic ABD (amoxicillin/clavulanic acid 500/125 mg 2 times a day) and mucolytic drugs (acetylcysteine 600 mg 1 time per day); 2^nd group patients (n = 45; mean age 45.9 ± 3.6 years) were administered Fluimucyl Antimicrobiotic IT at a dose of 500 mg per day by inhalation with nebulizer for 6 days. Results. According to the data of the conducted study the significant advantages of the use of inhalation ABD with mucolytic effect in the treatment of patients with acute CB in comparison with systemic ABD in combination with tableted acetylcysteine in the form of shortness of breath, cough, sputum excretion, improvement of patients quality of life in general are demonstrated. Conclusion. In most cases, when used in outpatient practice safe, with a good profile of sensitivity and resistance of inhalation ABD with mucolytic effect significantly improves the quality of management of patients with infectious CB exacerbation.